Home / Posts Tagged "Biologics"

Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and nine months ended December 31st, 2024. Key Financial Highlights Q3 FY25 Highlights Revenue from operations at Rs. 52,691 mn, up 17% over last year. Research & Development (R&D) investments for the quarter stood

READ MORE

Mankind Pharma Limited (BSE: 543904 | NSE: MANKIND) and Innovent Biologics have announced a groundbreaking partnership to exclusively license and commercialize sintilimab, an advanced PD-1 immunotherapy, in the Indian market. This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient

READ MORE

Gland Pharma Limited (BSE: 543245 I NSE: GLAND), a generic injectable-focused pharmaceutical company, today announced its financial results for the Second quarter (Q2FY25) ended on September 30th, 2024. Financial Highlights Q2 FY25 (July 2024 to September 2024) • Consolidated revenue increased 2% year-over-year to INR 14,058 million. • Consolidated EBITDA decreased

READ MORE

Revenue from operations increased sequentially by 13% to Rs. 891 crores, down 2% year-on-year First half FY25 revenue was broadly flat, in line with our guidance, at Rs. 1,681 crores Syngene International Limited today announced its second quarter and half year financial results. Revenue from

READ MORE

OneSource Specialty Pharma, a newly formed CDMO, is formed from the merger of three CDMO businesses within the Strides Group, which boasts a 30-year track-record of excellence in manufacturing and quality. The company is launching its new brand identity with a strong emphasis on customer

READ MORE

Expands high entry barrier portfolio; Leadership in Women’s Health (#1 in Gynae IPM[i]) High entry barrier portfolio with specialty R&D tech platforms across - Recombinants, Niche Biologics, Novel Delivery and Immunoglobulins Only innovator in the world to develop patented recombinant Anti-D Brands across Women’s Health

READ MORE

FY2024 Performance Highlights Highest ever full-year Revenue of ₹40,555 million in FY24, up 14.4% YoY Highest ever full-year EBITDA of ₹7,477 million in FY24, up 77.6% YoY US business achieved top end of $250 million revenue outlook for FY24, grew by 11.8% YoY Net

READ MORE

  In a significant stride towards enhancing global health security and pandemic preparedness, TechInvention Lifecare Pvt. Ltd. is proud to announce the ground breaking of its Global Collaborative Centre for Medical Countermeasures (GCMC) with an investment of approx. USD 15 million. The centre is strategically located

READ MORE